Saturday 17 October 2026
Export TNYA’s income statement to Excel — free account
Tenaya Therapeutics, Inc.
TNYA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 42.9% and free cash flow grew 76.5%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
0.38
0.03
−7.32%
Follow TNYA
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|
Current Ratio |
6.84 | 4.22 | 4.91 | 7.99 | 11.73 | 25.78 | 6.73 | — |
Net Debt/EBITDA |
1.19 | 0.57 | 0.86 | 1.56 | 3.60 | 3.53 | 1.04 | — |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.75 | 0.81 | 0.82 | 0.84 | 0.84 | 0.92 | 0.92 | — |
Capex/Depreciation |
(0.07) | (0.12) | (0.14) | (3.35) | (8.12) | (3.93) | (1.47) | — |
| (83.84%) | (95.69%) | (64.83%) | (47.39%) | (73.75%) | 61.41% | 42.01% | — | |
| (67.90%) | (76.52%) | (55.21%) | (41.70%) | (31.46%) | (41.25%) | (138.05%) | — | |
ROIC |
(256.77%) | (230.73%) | (235.74%) | (138.11%) | (167.13%) | (223.04%) | (646.75%) | — |
Return on Tangible Assets |
(76.89%) | (127.36%) | (93.91%) | (56.07%) | (26.29%) | (27.02%) | (79.02%) | — |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Free Cash Flow per Share |
(0.45) | (1.08) | (1.40) | (2.79) | (4.85) | (46.51) | (35.74) | — |
Cash per Share |
0.66 | 0.72 | 1.42 | 4.16 | 14.17 | 132.24 | 35.22 | — |
Shareholders Equity per Share |
0.81 | 1.09 | 1.89 | 5.43 | 15.71 | 143.46 | 38.76 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
0.81 | 1.09 | 1.89 | 5.43 | 15.71 | 143.46 | 38.76 | — |
Free Cash Flow |
(68.88) | (91.53) | (103.31) | (125.05) | (85.93) | (45.21) | (27.02) | — |
Working Capital |
90.15 | 51.40 | 88.85 | 169.51 | 233.58 | 124.92 | 23.62 | — |
Capital Expenditures |
(0.62) | (1.02) | (1.24) | (20.63) | (25.12) | (9.76) | (2.93) | — |
Net Current Asset Value |
81.93 | 40.29 | 80.49 | 158.19 | 219.70 | 121.24 | 19.04 | — |
| Other line items | ||||||||
Quick Ratio |
6.51 | 3.85 | 4.60 | 7.69 | 11.54 | 25.50 | 6.46 | — |
Depreciation/Fixed assets |
0.32 | 0.23 | 0.21 | 0.12 | 0.07 | 0.14 | 0.21 | — |
Cash ROIC |
(30.78%) | (59.32%) | (42.33%) | (29.09%) | (16.22%) | (16.87%) | (48.32%) | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.45) | (1.07) | (1.38) | (2.33) | (3.43) | (36.47) | (31.87) | — |
Capex per Share |
0.00 | (0.01) | (0.02) | (0.46) | (1.42) | (10.04) | (3.87) | — |
Average Payables |
4.37 | 5.40 | 7.60 | 10.15 | 5.87 | 0.81 | 0.81 | — |
Average Assets |
133.43 | 145.23 | 224.73 | 296.57 | 231.18 | 93.08 | 19.00 | — |
Average Common Equity |
108.06 | 116.14 | 191.40 | 260.95 | 98.61 | (62.53) | (62.44) | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates